The sentence going around: Medicare now covers $500 of CBD a year. The number is real. The word “covers” is doing work it hasn’t earned.
CMS’s page for the Substance Access Beneficiary Engagement Incentive says participants “may elect to furnish such hemp products up to $500 a year, per eligible beneficiary.” Beneath it, the line most coverage skips: “Medicare does not pay the participant for the products, and beneficiaries should not be asked to submit a Medicare claim for the product.”
So it isn’t reimbursement. It’s a provider handing you a bottle it bought itself.
Who would actually hand it to you
The incentive is optional and lives in three CMS Innovation Center models: ACO REACH, the Enhancing Oncology Model and LEAD. Participants in the first two could begin April 1, 2026; LEAD joins January 1, 2027.
An organization must elect it, file an implementation plan naming products and dosing, and win CMS approval. Only 74 ACOs are in ACO REACH this year; CMS says the model is closed to new applicants and ends with performance year 2026.
Products must come directly from a qualified physician affiliated with the participating organization, and CMS says participants cannot tell you to buy at retail and submit receipts.
One gate removes whole states at once: CMS says the incentive is available only to participants in states where the eligible hemp products are legal. Don’t assume your doctor offers it; ask before budgeting around it.
The product rules read like a COA checklist
Eligible products are capped at 0.3% delta-9 THC and exclude inhalables, anything over 3 mg per serving of tetrahydrocannabinols taken orally, and cannabinoids the plant can’t make. CMS also requires third-party testing for potency, contaminants and microbial hazards, with negative results.
Read the lab sheet, not the label. CMS has made that sheet a condition of eligibility.
The calendar
The D.C. Circuit’s scheduling order in No. 26-5205, reported August 27, sets appellants’ brief for October 5, appellees’ for November 4, a reply November 25 and final briefs December 16 — two weeks before ACO REACH’s final performance year runs out. The challenge, brought by Smart Approaches to Marijuana, MMJ International Holdings and others, was dismissed in May by Judge Trevor N. McFadden for lack of standing.
Notice the briefing runs past November 12, when the federal per-container standard is due to land. A 3 mg-per-serving allowance and a per-container total-THC cap are not obviously compatible; CMS says only that it will adjust its definition to match the law.
What it’s worth to you
Our usual lens doesn’t fit: $500 you can’t spend has no price per milligram, and the buying decision isn’t yours. A physician handing over a bottle doesn’t make it medicine: the FDA has evaluated none of these products, none is intended to diagnose, treat, cure or prevent any disease, and this is an adults-only category — CMS starts eligibility at 18.